NextCure, Inc. Files 8-K Report
Ticker: NXTC · Form: 8-K · Filed: Dec 19, 2025 · CIK: 1661059
| Field | Detail |
|---|---|
| Company | Nextcure, Inc. (NXTC) |
| Form Type | 8-K |
| Filed Date | Dec 19, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $14,500,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k
TL;DR
NextCure filed an 8-K, standard procedure, no major news yet.
AI Summary
On December 19, 2025, NextCure, Inc. filed an 8-K report. The filing indicates that the company is a pharmaceutical preparations company incorporated in Delaware with its principal executive offices located in Beltsville, Maryland. No specific events or financial details are provided in the excerpt.
Why It Matters
This filing serves as an official notification to the SEC and the public about the company's status and reporting requirements.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report and does not contain any specific material events or financial disclosures that would indicate immediate risk.
Key Players & Entities
- NextCure, Inc. (company) — Registrant
- December 19, 2025 (date) — Date of earliest event reported
- Beltsville, Maryland (location) — Principal executive offices
- 240-399-4900 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing for NextCure, Inc.?
The 8-K filing is a Current Report required by the SEC to inform the public of material events that occur between required filings.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on December 19, 2025.
Where are NextCure, Inc.'s principal executive offices located?
NextCure, Inc.'s principal executive offices are located at 9000 Virginia Manor Road, Suite 200, Beltsville, Maryland 20705.
What is NextCure, Inc.'s IRS Employer Identification Number?
NextCure, Inc.'s IRS Employer Identification Number is 47-5231247.
Under which section of the Securities Exchange Act of 1934 is this Form 8-K filed?
This Form 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 926 words · 4 min read · ~3 pages · Grade level 11.2 · Accepted 2025-12-19 17:31:12
Key Financial Figures
- $0.001 — e on which registered Common Stock, $0.001 par value per share NXTC Nasdaq Globa
- $14,500,000 — time, up to an aggregate sales price of $14,500,000 of its common stock, $0.001 par value p
Filing Documents
- tm2533962d1_8k.htm (8-K) — 31KB
- tm2533962d1_ex1-1.htm (EX-1.1) — 231KB
- tm2533962d1_ex5-1.htm (EX-5.1) — 16KB
- tm2533962d1_ex5-1img01.jpg (GRAPHIC) — 2KB
- tm2533962d1_ex5-1img02.jpg (GRAPHIC) — 2KB
- tm2533962d1_ex5-1img03.jpg (GRAPHIC) — 2KB
- 0001104659-25-123305.txt ( ) — 508KB
- nxtc-20251219.xsd (EX-101.SCH) — 3KB
- nxtc-20251219_lab.xml (EX-101.LAB) — 33KB
- nxtc-20251219_pre.xml (EX-101.PRE) — 22KB
- tm2533962d1_8k_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On December 19, 2025, NextCure, Inc. (the "Company") entered into an at the market offering agreement (the "ATM Agreement") with H.C. Wainwright & Co., LLC (the "Agent"), pursuant to which the Company may sell, from time to time, up to an aggregate sales price of $14,500,000 of its common stock, $0.001 par value per share (the "Common Stock"), through the Agent. Actual sales will depend on a variety of factors to be determined by the Company from time to time, including, among other things, market conditions, the trading price of the Common Stock, capital needs and determinations by the Company of the appropriate sources of funding for the Company. The Common Stock sold in the offering will be issued pursuant to a prospectus supplement filed with the Securities and Exchange Commission (the "SEC") on December 19, 2025, and the accompanying base prospectus dated August 4, 2023, forming part of the Company's registration statement on Form S-3 (Registration No. 333-273723). Sales of the Common Stock, if any, made pursuant to the ATM Agreement may be sold in negotiated transactions or transactions that are deemed to be an "at the market offering", as defined in Rule 415(a)(4) of the Securities Act of 1933, as amended (the "Securities Act"), including sales made directly on or through the Nasdaq Global Select Market, on or through any other existing trading market for the Common Stock or by any other method permitted by law, at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices, or as otherwise agreed between the Company and the Agent. The Agent will be entitled to compensation equal to 3.0% of the gross proceeds from the sale of all shares of Common Stock sold under the ATM Agreement. The Company intends to use any net proceeds from the offering, if any, for general corporate purposes and working capital, including for preclinical studies and clinical trials and the advancement
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 1.1 ATM Agreement, dated December 19, 2025, between the Company and H.C. Wainwright & Co., LLC 5.1 Opinion of Sidley Austin LLP regarding the legality of the Common Stock 23.1 Consent of Sidley Austin LLP (included in Exhibit 5.1) 104 Cover Page Interactive Data File (formatted as inline XBRL). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: December 19, 2025 NEXTCURE, INC. By: /s/ Steven P. Cobourn Name: Steven P. Cobourn Title: Chief Financial Officer